Eckert & Ziegler surges on EUR 100 mln cancer treatment order

Eckert & Ziegler SE

26/09/2023 07:19

** Shares in Eckert & Ziegler  EUZG.DE  surge 8% in the
early Frankfurt trade after the German medtech group won a 100
million euros ($105.83 million) order from POINT Pharma  PNT.O ,
a U.S. radiopharmaceutical firm 
    ** The contract includes supplies of the Lutetium-177, an
isotope used in cancer treatment, over 10 years, and will start
contributing to revenues from 2023 on, the company says 
    ** "10 mln euros in revenues each year means almost 5% of
FY23 expected revenues," a local trader says 
    ** Following the deal, Eckert & Ziegler is planning to
expand its Lutetium-177 production capacities by investing 10
million euros in its Wilmington plant 
    
($1 = 0.9449 euros)

 (Reporting by Andrey Sychev)
 ((Andrey.Sychev2@thomsonreuters.com))